S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.52 (+1.01%)
AAPL   173.11 (+0.41%)
MSFT   318.19 (+1.53%)
META   303.74 (+0.93%)
GOOGL   134.76 (+1.76%)
AMZN   126.42 (+1.36%)
TSLA   256.94 (+4.22%)
NVDA   437.67 (+0.57%)
NIO   8.74 (+1.51%)
BABA   84.03 (-0.60%)
AMD   102.32 (+2.24%)
T   14.60 (-1.22%)
F   12.01 (-0.50%)
MU   67.89 (+0.09%)
CGC   0.75 (+9.95%)
GE   108.97 (+1.12%)
DIS   79.56 (+0.03%)
AMC   8.04 (+2.42%)
PFE   33.56 (-1.00%)
PYPL   58.18 (+1.54%)
NFLX   376.39 (-0.10%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.52 (+1.01%)
AAPL   173.11 (+0.41%)
MSFT   318.19 (+1.53%)
META   303.74 (+0.93%)
GOOGL   134.76 (+1.76%)
AMZN   126.42 (+1.36%)
TSLA   256.94 (+4.22%)
NVDA   437.67 (+0.57%)
NIO   8.74 (+1.51%)
BABA   84.03 (-0.60%)
AMD   102.32 (+2.24%)
T   14.60 (-1.22%)
F   12.01 (-0.50%)
MU   67.89 (+0.09%)
CGC   0.75 (+9.95%)
GE   108.97 (+1.12%)
DIS   79.56 (+0.03%)
AMC   8.04 (+2.42%)
PFE   33.56 (-1.00%)
PYPL   58.18 (+1.54%)
NFLX   376.39 (-0.10%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.52 (+1.01%)
AAPL   173.11 (+0.41%)
MSFT   318.19 (+1.53%)
META   303.74 (+0.93%)
GOOGL   134.76 (+1.76%)
AMZN   126.42 (+1.36%)
TSLA   256.94 (+4.22%)
NVDA   437.67 (+0.57%)
NIO   8.74 (+1.51%)
BABA   84.03 (-0.60%)
AMD   102.32 (+2.24%)
T   14.60 (-1.22%)
F   12.01 (-0.50%)
MU   67.89 (+0.09%)
CGC   0.75 (+9.95%)
GE   108.97 (+1.12%)
DIS   79.56 (+0.03%)
AMC   8.04 (+2.42%)
PFE   33.56 (-1.00%)
PYPL   58.18 (+1.54%)
NFLX   376.39 (-0.10%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.52 (+1.01%)
AAPL   173.11 (+0.41%)
MSFT   318.19 (+1.53%)
META   303.74 (+0.93%)
GOOGL   134.76 (+1.76%)
AMZN   126.42 (+1.36%)
TSLA   256.94 (+4.22%)
NVDA   437.67 (+0.57%)
NIO   8.74 (+1.51%)
BABA   84.03 (-0.60%)
AMD   102.32 (+2.24%)
T   14.60 (-1.22%)
F   12.01 (-0.50%)
MU   67.89 (+0.09%)
CGC   0.75 (+9.95%)
GE   108.97 (+1.12%)
DIS   79.56 (+0.03%)
AMC   8.04 (+2.42%)
PFE   33.56 (-1.00%)
PYPL   58.18 (+1.54%)
NFLX   376.39 (-0.10%)
NASDAQ:AKRO

Akero Therapeutics (AKRO) Price Target & Analyst Ratings

$46.40
-1.06 (-2.23%)
(As of 12:46 PM ET)
Compare
Today's Range
$45.95
$48.12
50-Day Range
$41.19
$52.25
52-Week Range
$35.36
$58.38
Volume
175,254 shs
Average Volume
685,176 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.86

Akero Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$65.86
41.93% Upside
High Prediction$83.00
Average Prediction$65.86
Low Prediction$58.00
TypeCurrent
10/4/22 to 10/4/23
1 Month Ago
9/4/22 to 9/4/23
3 Months Ago
7/6/22 to 7/6/23
1 Year Ago
10/4/21 to 10/4/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$65.86$57.50$52.40$41.75
Predicted Upside41.93% Upside41.76% Upside34.65% Upside50.37% Upside
Get Akero Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.


AKRO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akero Therapeutics Stock vs. The Competition

TypeAkero TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside38.76% Upside867.56% Upside701.33% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/4/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$69.00+46.31%
9/13/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$50.00 ➝ $60.00+18.13%
9/5/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$49.00 ➝ $62.00+24.65%
8/28/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$83.00+73.02%
6/7/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$62.00 ➝ $64.00+20.21%
4/11/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Dolezal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/21/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$50.00 ➝ $58.00+49.45%
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$40.00 ➝ $65.00+36.41%
(Data available from 10/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AKRO Price Target - Frequently Asked Questions

What is Akero Therapeutics's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Akero Therapeutics stock is Buy based on the current 8 buy ratings for AKRO. The average twelve-month price prediction for Akero Therapeutics is $65.86 with a high price target of $83.00 and a low price target of $58.00. Learn more on AKRO's analyst rating history.

Do Wall Street analysts like Akero Therapeutics more than its competitors?

Analysts like Akero Therapeutics more than other Medical companies. The consensus rating for Akero Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how AKRO compares to other companies.

Does Akero Therapeutics's stock price have much upside?

According to analysts, Akero Therapeutics's stock has a predicted upside of 40.56% based on their 12-month price targets.

What analysts cover Akero Therapeutics?

Akero Therapeutics has been rated by Cantor Fitzgerald, Evercore ISI, JPMorgan Chase & Co., and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AKRO) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -